%0 Journal Article
%T Tolerability and clinical efficacy of inhaled treprostinil in
patients with group 1 pulmonary arterial hypertension
%A Charles Burger
%A Cher Y. Enderby
%J Archive of "Therapeutic Advances in Chronic Disease".
%D 2018
%R 10.1177/2040622318779749
%X Treprostinil is a prostacyclin analogue that directly vasodilates pulmonary and systemic arterial vascular beds. The United States Food and Drug Administration approved inhaled treprostinil in July 2009 for the treatment of group 1 pulmonary arterial hypertension. Inhaled treprostinil avoids issues with continuous infusion prostanoids. This study describes a single institutional experience with inhaled treprostinil
%K treprostinil
%K pulmonary arterial hypertension
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6116084/